Immix Biopharma enters ATM equity offering with Citizens JMP Securities

Immix Biopharma, Inc.

Agreement allows at-the-market sales of common stock; 3% commission to Agent.
Sales conducted under existing S-3 shelf (File No. 333-269100), filed January 2023.
No immediate sale; company controls timing, price, and size of any offerings.
Agent indemnified and reimbursed up to $50,000 for specified expenses.
Shares subject to registration limits and Nasdaq rules.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.